Last reviewed · How we verify

0.25% bupivacaine with 1:200,000 epinephrine

Jessyka Lighthall · Phase 3 active Small molecule Quality 0/100

0.25% bupivacaine with 1:200,000 epinephrine is a Small molecule drug developed by Jessyka Lighthall. It is currently in Phase 3 development.

At a glance

Generic name0.25% bupivacaine with 1:200,000 epinephrine
SponsorJessyka Lighthall
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 0.25% bupivacaine with 1:200,000 epinephrine

What is 0.25% bupivacaine with 1:200,000 epinephrine?

0.25% bupivacaine with 1:200,000 epinephrine is a Small molecule drug developed by Jessyka Lighthall.

Who makes 0.25% bupivacaine with 1:200,000 epinephrine?

0.25% bupivacaine with 1:200,000 epinephrine is developed by Jessyka Lighthall (see full Jessyka Lighthall pipeline at /company/jessyka-lighthall).

What development phase is 0.25% bupivacaine with 1:200,000 epinephrine in?

0.25% bupivacaine with 1:200,000 epinephrine is in Phase 3.

Related